Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 50 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 8080246

    Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules

    Five Prime Therapeutics, Inc. · Granted Dec 20, 2011 · Expires Dec 15, 2031

    granted

  2. US 8058025

    Methods for determining efficacy of chemotherapeutic agents

    Precision Therapeutics, Inc. · Granted Nov 15, 2011 · Expires Nov 10, 2031

    granted

  3. US 8058257

    Compositions and methods for inhibiting expression of a gene from the JC virus

    Alnylam Pharmaceuticals, Inc. · Granted Nov 15, 2011 · Expires Nov 10, 2031

    granted

  4. US 8048646

    NELL peptide expression systems and bone formation activity of NELL peptide

    The Regents of the University of California · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  5. US 8030493

    Monovalent and divalent salts of N-(5-hydroxynicotinoil) -L-glutamic acid exhibiting psychotropic (antidepressant and anxiolytic), neuroprotective, geroprotective and cerebroprotective action

    Obschestvo S Ogranichennoy Otvetstvennostyu “Natsionalnaya Isseldovatelskaya Kompaniya” · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  6. US 8022052

    Inhibition of PPAR gamma expression by specific osteogenic oxysterols

    The Regents of the University of California · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  7. US 8017321

    Gefitinib sensitivity-related gene expression and products and methods related thereto

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 13, 2011 · Expires Sep 8, 2031

    granted

  8. US 8003619

    Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide

    Alnylam Pharmaceuticals, Inc. · Granted Aug 23, 2011 · Expires Aug 18, 2031

    granted

  9. US 7998682

    Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Aug 16, 2011 · Expires Aug 11, 2031

    granted

  10. US 7994307

    RNAi modulation of the BCR-ABL fusion gene and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  11. US 7994309

    Compositions and methods for inhibiting expression of a mutant gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2011 · Expires Aug 4, 2031

    granted

  12. US 7985581

    Multiple RNA polymerase III promoter expression constructs

    Alnylam Pharmaceuticals, Inc. · Granted Jul 26, 2011 · Expires Jul 21, 2031

    granted

  13. US 7985887

    Regulation of endogenous gene expression in cells using zinc finger proteins

    Sangamo Biosciences, Inc. · Granted Jul 26, 2011 · Expires Jul 21, 2031

    granted

  14. US 7982014

    FGFR3-IIIc fusion proteins

    Five Prime Therapeutics, Inc. · Granted Jul 19, 2011 · Expires Jul 14, 2031

    granted

  15. US 7981610

    ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)

    The United States of America, as represented by the Department of Health and Human Services · Granted Jul 19, 2011 · Expires Jul 14, 2031

    granted

  16. US 7977457

    Fusion proteins, uses thereof and processes for producing same

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 12, 2011 · Expires Jul 7, 2031

    granted

  17. US 7972601

    Method of promoting delivery of an antioxidant agent to a cell expression neuroligin

    The Regents of the University of California · Granted Jul 5, 2011 · Expires Jun 30, 2031

    granted

  18. US 7972598

    VEGF-binding fusion proteins and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 5, 2011 · Expires Jun 30, 2031

    granted

  19. US 7973020

    Compositions and methods for inhibiting expression of a gene from the ebola virus

    The United States of America as represented by the Secretary of the Army · Granted Jul 5, 2011 · Expires Jun 30, 2031

    granted

  20. US 7964710

    EML4-ALK fusion gene

    CUREGENE K.K. · Granted Jun 21, 2011 · Expires Jun 16, 2031

    granted

  21. US 7964573

    Regulating expression of transient receptor potential channel genes

    The Regents of the University of California · Granted Jun 21, 2011 · Expires Jun 16, 2031

    granted

  22. US 7964377

    Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2011 · Expires Jun 16, 2031

    granted

  23. US 7960416

    Stable emulsion composition

    Takeda Pharmaceutical Company Limited · Granted Jun 14, 2011 · Expires Jun 9, 2031

    granted

  24. US 7959925

    Trimeric OX40-immunoglobulin fusion protein and methods of use

    Providence Health System · Granted Jun 14, 2011 · Expires Jun 9, 2031

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.